Alector (ALEC) Wednesday said that GSK had terminated their neuroscience collaboration deal covering two experimental antibody drugs after both the drug candidates suffered clinical setbacks. Alector (ALEC) shares dropped 13% in extended trading, GSK eased 1.5%.
